Blinatumomab Monotherapy Seems Effective for DLBCL

Share this content:
Blinatumomab monotherapy appeared to be effective in patients with relapsed/refractory diffuse large B-cell lymphoma.
Blinatumomab monotherapy appeared to be effective in patients with relapsed/refractory diffuse large B-cell lymphoma.

Blinatumomab, a bispecific T-cell engaging (BiTE) antibody construct, monotherapy appeared to be effective in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).1

Because few patients with relapsed/refractory DLBCL achieve prolonged disease-free survival, researchers sought to evaluate the effect of blinatumomab monotherapy on treatment outcomes on this heavily pretreated patient population with a high unmet medical need.

For the phase 2 study, researchers enrolled 25 heavily pretreated patients with DLBCL. Patients were assigned to receive blinatumumab 112 μg daily infused continuously or in a weekly stepwise dose-escalation fashion from 9 to 28 to 112 μg daily, plus dexamethasone prophylaxis. Patients had received a median of 3 prior lines of therapy and it had been a median of 1.5 months since their last regimen.

Results showed that among 21 evaluable patients, the overall response rate after 1 blinatumomab cycle was 43%, including a 19% complete response rate. Researchers found that 3 patients had late complete responses during follow-up without other treatment.

In regard to safety, the most common adverse events with the stepwise dosing schema were tremors, pyrexia, fatigue, and edema. Grade 3 neurologic events in the same group included encephalopathy, aphasia, tremors, speech disorders, dizziness, somnolence, and disorientation.

RELATED: Study Confirms PET-CT as Modern Standard for Staging Hodgkin Lymphoma

The cohort that received 112 μg daily was stopped because of grade 3 neurologic events in the only 2 patients in the group. Five patients in the stepwise-dosing group discontinued treatment due to adverse events; however, most neurologic events resolved.

“Further studies need to define the optimal approach to achieve the target dose without early dropout,” the authors noted.

Reference

  1. Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in relapsed/refractory diffuse large B cell lymphoma [published online ahead of print January 11, 2016]. Blood. doi: 10.1182/blood-2015-06-651380.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters